Eric Skolnik - Apr 22, 2022 Form 4 Insider Report for BLONDER TONGUE LABORATORIES INC (BDRL)

Role: SVP - CFO
Signature: /s/ Eric Skolnik
Stock symbol: BDRL
Transactions as of: Apr 22, 2022
Transactions value $: $2,452
Form type: 4
Date filed: 4/25/2022, 04:27 PM
Previous filing: Apr 11, 2022
Next filing: May 9, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BDRL	Common Stock, par value $0.001	Award	$529	+766	+1.63%	$0.69	47.8K	Apr 22, 2022	Direct	F1
transaction	BDRL	Common Stock, par value $0.001	Award	$1.92K	+2.79K	+5.82%	$0.69	50.6K	Apr 22, 2022	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Pursuant to a Deferred Compensation Agreement between the reporting person and the issuer, on the date on which a portion of the reporting person's compensation has been deferred, the issuer accrued the number of shares indicated. The number of shares of common stock accrued represents the quotient of (i) the portion of compensation deferred divided by (ii) the fair market value per share of the issuer's common stock on the indicated date (equal to the closing price reported on the NYSE American on such date).
F2	Pursuant to the participation in the Second Amended and Restated Executive Stock Purchase Plan between the reporting person and the issuer, on the date on which a portion of the reporting person's net cash compensation has been reduced, the issuer issued the number of shares indicated. The number of shares of common stock issued represents the quotient of (i) the portion of the net cash compensation reduction divided by (ii) the fair market value per share of the issuer's common stock on the indicated date (equal to the closing price reported on the NYSE American on such date).

Content

Pursuant to a Deferred Compensation Agreement between the reporting person and the issuer, on the date on which a portion of the reporting person's compensation has been deferred, the issuer accrued the number of shares indicated. The number of shares of common stock accrued represents the quotient of (i) the portion of compensation deferred divided by (ii) the fair market value per share of the issuer's common stock on the indicated date (equal to the closing price reported on the NYSE American on such date).

Pursuant to the participation in the Second Amended and Restated Executive Stock Purchase Plan between the reporting person and the issuer, on the date on which a portion of the reporting person's net cash compensation has been reduced, the issuer issued the number of shares indicated. The number of shares of common stock issued represents the quotient of (i) the portion of the net cash compensation reduction divided by (ii) the fair market value per share of the issuer's common stock on the indicated date (equal to the closing price reported on the NYSE American on such date).